RAM
PTCT icon

Riggs Asset Management’s PTC Therapeutics PTCT Stock Holding History

Riggs Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11
Closed -$538 – 670
2025
Q2 		$538 Hold
11
– – ﹤0.01% 833
2025
Q1 		$561 Hold
11
– – ﹤0.01% 550
2024
Q4 		$504 Hold
11
– – ﹤0.01% 545
2024
Q3 		$409 Hold
11
– – ﹤0.01% 570
2024
Q2 		$337 Hold
11
– – ﹤0.01% 589
2024
Q1 		$320 Buy
+11
New +$308 ﹤0.01% 610

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Riggs Asset Management's PTCT Position: Q3 2025 in Review

Riggs Asset Management sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 11 shares — an estimated $538 sold.

Riggs Asset Management first reported a position in PTCT in Q1 2024 and held it in 6 quarters. The position peaked at $561 in Q1 2025. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • Riggs Asset Management reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Riggs Asset Management sold 11 PTC Therapeutics shares in Q3 2025, an estimated $538.
  • Riggs Asset Management first reported a position in PTC Therapeutics in Q1 2024 and held it in 6 quarters.
  • Riggs Asset Management's PTC Therapeutics position peaked at $561 in Q1 2025.
  • 293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Riggs Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.